Dunn LA, et al. - This trial entailed the examination of the inclusion of afatinib, an ErbB family inhibitor, and ribavirin to paclitaxel and carboplatin induction chemotherapy in human papillomavirus (HPV)-associated, locally advanced oropharyngeal squamous cell carcinoma (SCC). It was reported that afatinib, ribavirin, paclitaxel, and carboplatin induction chemotherapy was safe and well tolerated. The phase II trial suggested the administration of the dose of afatinib 40 mg oral daily in this combination regimen.